Unicycive Therapeutics Inc (NASDAQ:UNCY) does about 1.31M shares in volume on a normal day but saw 21057759 shares change hands in the recent trading day. The company now has a market cap of 108.57M USD. Its current market price is $0.90, marking an increase of 19.30% compared to the previous close of $0.75. The 52 week high reached by this stock is $0.87 whilst the lowest price level in 52 weeks is $0.20.
The consensus objective for the share price is $7.00, suggesting that the stock has a potential upside of 87.14% over the period.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 21, 2025 when Guggenheim initiated the stock to “Buy” and issued a price target of $6.
The current price level is 41.14%, 47.44%, and 60.61% away from its SMA20, SMA50, and SMA200 respectively, with the UNCY price moving below the 50-day SMA on current market day. Unicycive Therapeutics Inc (UNCY) stock is up 35.87% over the week and 44.67% over the past month. Its price is 13.32% year-to-date and 15.38% over the past year.
To reach the target analysts have set, the stock logically needs to grow 87.14 percent from here.
Outstanding shares total 119.75M with insiders holding 5.22% of the shares and institutional holders owning 52.50% of the company’s common stock. The company has a return on investment of -195.79% and return on equity of -2355.27%. The forward price to earnings ratio is 0.49. The beta has a value of 2.02. Price to book ratio is 9.56.
